艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

交易中 07-09 09:54:04 EDT

77.79

-0.13

-0.17%

最高78.13	最低77.61	成交量1.29万
今开78.04	昨收77.92	日振幅0.66%
总市值93.37亿	流通市值91.72亿	总股本1.20亿
成交额100.54万	换手率0.01%	流通股本1.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":77.79,"timestamp":1783605236938,"preClose":77.92,"halted":0,"volume":12908,"delay":0,"changeRate":-0.001668377823408566,"floatShares":117901774,"shares":120028300,"eps":1.85165,"marketStatus":"交易中","change":-0.13,"latestTime":"07-09 09:54:04 EDT","open":78.04,"high":78.125,"low":77.61,"amount":1005433.67932,"amplitude":0.006609,"askPrice":77.96,"askSize":15,"bidPrice":77.57,"bidSize":144,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1783627200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":77.92,"dividendRate":0.039949,"preHourTrading":{"tag":"盘前","latestPrice":77.92,"preClose":77.92,"latestTime":"09:21 EDT","volume":21,"amount":1642.37136,"timestamp":1783603302275,"change":0,"changeRate":0,"amplitude":0.031924},"postHourTrading":{"tag":"盘后","latestPrice":79.09,"preClose":77.92,"latestTime":"18:08 EDT","volume":47614,"amount":3710263.3525,"timestamp":1783548495395,"change":1.17,"changeRate":0.015015,"amplitude":0.015015},"volumeRatio":0.170318,"impliedVol":0.2328,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2649137647","title":"从“旁观者”到“追赶者”：诺华(NVS.US)斥资15亿美元收购Myricx，ADC赛道再落关键一子","url":"https://stock-news.laohu8.com/highlight/detail?id=2649137647","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649137647?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:02","pubTimestamp":1783328521,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华已就收购英国生物技术企业Myricx Bio达成协议，交易总对价最高可达15亿美元。据诺华周一发布声明，Myricx股东将获得11亿美元预付款，以及最高4亿美元的潜在里程碑付款。2025年10月，诺华以120亿美元收购了Avidity Biosciences，成为当年规模最大的抗体相关交易。此次收购Myricx，正是其深耕肿瘤学核心领域、充实ADC管线的关键落子。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","MEDX","LU0211331839.USD","BK4532","NVS","BK4588","LU0208291251.USD","IE00B4R5TH58.HKD","NETL","LU0070302665.USD","IE00B2B36J28.USD","ADC","BK4231","BK4007","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4080","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4578","IE0009355771.USD","IE0002141913.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649461757","title":"诺诚健华盘中涨超9% 自研靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2649461757","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649461757?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:52","pubTimestamp":1783302720,"startTime":"0","endTime":"0","summary":"　　诺诚健华盘中涨超9%，截至发稿，股价上涨6.42%，现报13.92港元，成交额5426.90万港元。　　7月6日，据诺诚健华官微消息，公司宣布自主研发的靶向CDH17的新型ADC创新药ICP-B208完成首例患者给药。基于诺诚健华自主研发的ADC技术平台，ICP-208由人源化抗CDH17抗体通过蛋白酶可裂解连接子与公司自主开发的强效有效载荷偶联而成，可精准靶向肿瘤细胞，同时最大限度减少脱靶效应。目前，全球尚无CDH17靶向ADC新药上市。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-06/doc-inifvqsf1795989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688428","09969","IBBQ","BK4080","MEDX","BK0239","NETL","BK1574","ADC","BK4231","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648630681","title":"博腾双载荷ADC IND成功交付","url":"https://stock-news.laohu8.com/highlight/detail?id=2648630681","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648630681?lang=zh_cn&edition=full","pubTime":"2026-07-03 11:05","pubTimestamp":1783047950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","ADC","IND","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648980686","title":"芯海科技：性能参数方面，功耗、安全、软件生态、ADC精度、主频均处于行业领先水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2648980686","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648980686?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:01","pubTimestamp":1783000860,"startTime":"0","endTime":"0","summary":"证券日报网7月2日讯，芯海科技在接受调研者提问时表示，性能参数方面，功耗、安全、软件生态、ADC精度、主频均处于行业领先水平。例如，传统EC主频通常为9.6兆，公司产品为百兆主频，除基础功能外可承担管理中枢作用，还具备AI相关能力；公司是全球首个联合联想发布基于Zephyr操作系统EC的厂商；公司推行IPD集成产品开发体系，保障产品高成熟度，是半导体行业为数不多横跨消费、工业、汽车三大领域的企业，产品已通过消费级、工业级、车规级相关品牌客户的认证。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmrts2638484.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-02/doc-inifmrts2638484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159180","BK4588","ADC","VGT","BK4585","BK0214","BK4231","688595","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504319","title":"石药集团：自主研发ADC药物SYS6043获纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504319","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648504319?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:57","pubTimestamp":1782989820,"startTime":"0","endTime":"0","summary":"南财智讯7月2日电，石药集团（01093.HK）发布自愿公告，公司自主研发的靶向B7-H3人源化单克隆抗体偶联药物SYS6043，已获国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为单药治疗铂耐药卵巢癌、原发性腹膜癌及输卵管癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023792065330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1521","IE0008369823.USD","LU1008478684.HKD","LU1328277881.USD","IE0008368742.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU0072913022.USD","01093","LU0326950275.SGD","LU0880133367.SGD","LU1951186391.HKD","HK0000165453.HKD","LU1993786604.SGD","LU0140636845.USD","LU1226288170.HKD","LU1226288253.USD","IE00B543WZ88.USD","BK1191","LU1960683339.HKD","LU1226287875.USD","LU0067412154.USD","SG9999004220.SGD","LU1152091754.HKD","BK4231","BK1515","LU0314109678.HKD","LU2039709279.SGD","LU1807302812.USD","IE00BZ08YT58.USD","LU0501845795.SGD","BK4080","ADC","IE00BZ08YS42.EUR","LU0315179316.USD","LU1226287792.SGD","LU1813983027.USD","LU1226287529.USD","IE00B5MMRT66.SGD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647801385","title":"双抗ADC新药宜泽康®在蓉首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2647801385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647801385?lang=zh_cn&edition=full","pubTime":"2026-06-30 14:56","pubTimestamp":1782802595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4080","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647358924","title":"【券商聚焦】国金证券：创新药企业扭亏节点已至 持续关注小核酸、双抗、ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2647358924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647358924?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:13","pubTimestamp":1782789198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。具体布局思路而言：(1)布局业绩财报窗口期，掘金业绩超预期标的；(2)关注学会大会动态，把握重磅临床数据发布窗口；(3)聚焦核心赛道，持续关注小核酸、双抗、ADC等相关标的的投资机会。风险提示：汇兑风险、投融资周期波动风险、并购整合不及预期的风险、数据安全与隐私合规风险等。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984822","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","159992","BK0012","BK1161","600109","BK0183","BK0188","ADC","BK0276","BK0028","BK1574","06978","BK4231","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645294190","title":"全球首个获批双抗ADC上市，百利天恒(688506.SH)加速向MNC跨代跃迁","url":"https://stock-news.laohu8.com/highlight/detail?id=2645294190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645294190?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126096,"startTime":"0","endTime":"0","summary":"作为全球首创EGFR×HER3双抗ADC，百利天恒的1类新药宜泽康在国内获批上市，用于复发/转移性鼻咽癌后线治疗。6月22日，百利天恒发布的这则重磅公告，引发了市场的广泛关注。本次获批，也标志着肿瘤治疗正式迈入双抗ADC新时代。此次在国内获批上市，是宜泽康加速成为“下一代基石癌症疗法”的第一步。该药由此成为全球第二款迈入III期临床开发的DLL3 ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688506","BK4080","BK0239","02615","IPOS","ADC","BK4231","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642250194","title":"港股异动 | 君实生物(01877)涨超5% 近日拟入股上海致域生物医药 布局ADC与多特异抗体研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250194","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642250194?lang=zh_cn&edition=full","pubTime":"2026-06-12 15:07","pubTimestamp":1781248026,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超5%，截至发稿，涨4.67%，报17.26港元，成交额6560.03万港元。消息面上，近日，君实生物发布公告，公司拟与苏州众合、君实工程、苏州君盟、合资公司上海致域生物医药有限公司及姚盛博士订立合资协议，据此，转让方有条件同意向合资公司授予许可知识产权的一项许可，用于许可产品的研究、开发、制造、使用及商业化；向合资公司转让有形资产；及向合资公司转让IP权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","BK4588","01877","XBI","BK4231","BK4581","399441","BK4080","ADC","VXUS","161726","BK1515","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642237365","title":"基石药业-B(02616)：CS5007(EGFR/HER3双特异性ADC)全球多中心I期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2642237365","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642237365?lang=zh_cn&edition=full","pubTime":"2026-06-12 06:10","pubTimestamp":1781215804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，本公司管线2.0核心候选药物CS5007的全球多中心I期临床试验，已正式获得澳大利亚人类研究伦理委员会的许可。这不仅标志着CS5007的全球临床开发全面启动，更意味着本公司管线2.0战略正加速兑现，后续重磅力量已进入临床快车道，有望为中长期增长持续注入信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","02616","BK1574","BK1161","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280708","title":"Immunome宣布IM-1617 ADC一期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280708","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642280708?lang=zh_cn&edition=full","pubTime":"2026-06-11 22:26","pubTimestamp":1781187960,"startTime":"0","endTime":"0","summary":"生物技术公司Immunome周三宣布，其潜在首创新药抗体偶联药物IM-1617的一期临床试验已完成首例患者给药。该药物针对一种未公开的实体瘤靶点，用于治疗晚期实体瘤患者。　　IM-1617是一款靶向实体瘤的抗体偶联药物，其靶向的是一种促进肿瘤细胞存活并介导免疫细胞排斥的受体酪氨酸激酶。该药物搭载了Immunome专有的拓扑异构酶I抑制剂HC74作为有效载荷。公司计划分别于2026年中和2026年末提交另外两款抗体偶联药物IM-1340和IM-1335的新药临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-11/doc-inicaenm0622024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","BK4231","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153816","title":"信达生物(01801): IBI343(CLDN18.2 ADC)治疗晚期胃癌的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153816?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:34","pubTimestamp":1780562045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，IBI343用于晚期胃癌人群的国际III期临床研究按预设方案完成第一次期中分析，达到主要研究终点，IBI343在晚期胃癌治疗中展现出了卓越的疗效和良好的安全性和耐受性。基于这一积极的临床结果，公司已向中国国家药品监督管理局递交IBI343的新药上市申请。IBI343是全球首个获监管审评受理的CLDN18.2靶向ADC药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828714.EUR","LU1969619763.USD","LU0455707207.USD","IPOS","LU2328871848.SGD","LU2242644610.SGD","HK0000165453.HKD","BK1161","LU2097828805.USD","LU0502904849.HKD","ADC","BK1589","01801","BK4231","LU2097828474.EUR","BK4080","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640140982","title":"中国生物制药双创新药闪耀ASCO：肺癌一线疗法PFS显著延长，全球首个EGFR/c-Met双抗ADC临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2640140982","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640140982?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"6月1日，中国生物制药（01177）发布公告，旗下附属公司正大天晴药业集团股份有限公司两项重磅创新药临床研究数据，于2026年美国临床肿瘤学会（ASCO）年会正式公布，涵盖肺癌一线治疗与全球首个EGFR/c-Met双抗ADC两大领域，疗效与安全性数据双双亮眼，彰显公司在肿瘤创新药领域的硬核实力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755509132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK4231","BK1589","159992","IE00BZ08YT58.USD","06978","BK4195","ADC","IE00BZ08YS42.EUR","HK0000165453.HKD","01177","BK1574","PFS","BK1521","BK1515","IE00BZ08YR35.GBP","BK4211","BK4080","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640398600","title":"中国生物制药(01177)：TQB6411“EGFR/C-MET ADC”于2026 ASCO公布I期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640398600","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640398600?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:53","pubTimestamp":1780267985,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB6411“EGFR/ c-Met ADC”于2026年美国临床肿瘤学会  大会上公布在晚期实体瘤患者中的首次人体I期临床研究数据。研究表明，TQB6411在有效剂量下呈现良好的安全性特征，尤其是血液学毒性较低。作为全球首批公布临床数据的EGFR/c-Met ADC，TQB6411凭借成熟的靶点组合及偏向c-Met端的亲和力设计，在降低研发风险的同时构建了差异化竞争优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","LU1989772923.USD","LU1496350502.SGD","LU1291159041.SGD","BK1191","BK1521","BK4585","ADC","HK0000165453.HKD","LU1989772840.SGD","IE00BZ08YT58.USD","LU1989771016.USD","BK4588","BK4080","BK4162","BK1515","IE00BZ08YS42.EUR","MET","IE00BZ08YR35.GBP","01177","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798605","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”于2026 ASCO公布一线胃癌II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798605","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640798605?lang=zh_cn&edition=full","pubTime":"2026-06-01 06:47","pubTimestamp":1780267642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的创新药维特柯妥拜单抗“CLDN18.2 ADC”于2026年美国临床肿瘤学会  大会上公布一线治疗胃或胃食管交界部腺癌的II期临床研究数据。结果显示，LM-302联合PD-1单抗  在CLDN18.2阳性晚期胃或胃食管结合部腺癌一线治疗中展现出令人鼓舞的抗肿瘤活性和可管理的安全性。治疗期间不良事件导致剂量降低的比例分别为17.9%和43.8%，导致治疗终止的比例分别为 23.1%和31.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK1589","ADC","BK4080","HK0000165453.HKD","BK1191","IE00BZ08YT58.USD","01177","IE00BZ08YS42.EUR","BK1515","IE00BZ08YR35.GBP","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988885","title":"科伦博泰研究成果发表于《柳叶刀》主刊","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988885","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639988885?lang=zh_cn&edition=full","pubTime":"2026-05-31 19:07","pubTimestamp":1780225625,"startTime":"0","endTime":"0","summary":"5月31日，四川科伦博泰生物医药股份有限公司宣布，其自主研发的抗体偶联药物芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床研究成果，正式发表于国际医学期刊《柳叶刀》主刊，研究同时入选2026年美国临床肿瘤学会年会口头报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=Hmeug%2Fbu0FE%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","ADC","BK4231","BK4211","BK4195","HR","PFS","BK4225","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639648279","title":"港股异动 | 德琪医药-B(06996)涨超5% ATG-022 ADC治疗相关胃腺癌关键性III期CLINCH-3研究获临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2639648279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639648279?lang=zh_cn&edition=full","pubTime":"2026-05-29 09:53","pubTimestamp":1780019635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德琪医药-B涨超5%，截至发稿，涨5.33%，报4.35港元，成交额327.19万港元。消息面上，德琪医药-B发布公告，经中国国家药品监督管理局(药监局)药品审评中心审评，本公司已获药审中心核准同意开展关于ATG-022用于治疗CLDN18.2+晚期胃或胃食管结合部腺癌的关键性III期CLINCH-3研究。本集团无法保证ATG-022最终将成功开发及上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","VXUS","BK1574","BK4588","ADC","BK4585","06996","BK4080","BK1191","BK1583","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687536","title":"艾伯维(ABBV.US)CD123 ADC获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638687536?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:36","pubTimestamp":1779953784,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维宣布美国FDA已经批准其ADC疗法Pivekimab sunirine上市，用于治疗母细胞性浆细胞样树突细胞肿瘤。资料显示，这是全球首个获批上市的CD123 ADC，也是艾伯维首个获批的血液瘤ADC。Pivekimab sunirine是一款靶向CD123的ADC，拟开发用于治疗血液系统恶性肿瘤。CD123靶点在BPDCN肿瘤细胞中呈高度特异性高表达，是该病理想的治疗靶点。美国FDA已于2020年10月授予该药物BPDCN适应症突破性疗法认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","IE0002270589.USD","BK4080","LU1718418525.SGD","IPOS","LU0158827948.USD","LU0289961442.SGD","LU1732799900.SGD","LU2357627491.SGD","LU0198837287.USD","ABBV","LU1267930573.SGD","BK4559","LU1244550494.USD","ADC","LU2133065610.SGD","LU0795875169.SGD","LU1023059063.AUD","LU2089984988.USD","LU0965509010.AUD","BK4566","IE00BLSP4239.USD","SG9999015978.USD","BK4533","IE00BVYPNV92.GBP","BK4581","SG9999011175.SGD","LU0211327993.USD","LU0289739343.SGD","LU0965509101.SGD","LU0661504455.SGD","IE000BZT7R73.USD","LU2089284900.SGD","LU0114720955.EUR","LU2237443465.HKD","IE0000B7K699.USD","SG9999003800.SGD","LU0965509283.SGD","LU1061106388.HKD","LU0472753341.HKD","LU1989771016.USD","IE00B42XCP33.USD","LU0820561909.HKD","LU1037948897.HKD","LU0029864427.USD","IE00BBT3K403.USD","LU1934455277.USD","LU1267930490.SGD","LU1839511570.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638457426","title":"港股异动 | 映恩生物-B(09606)涨超5% 与BioNTech合作开发B7-H3 ADC全球Ⅲ期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638457426","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638457426?lang=zh_cn&edition=full","pubTime":"2026-05-27 14:56","pubTimestamp":1779864979,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超5%，截至发稿，涨3.14%，报222.6港元，成交额1.52亿港元。消息面上，近日，据映恩生物-B官微消息，公司宣布，与BioNTech SE合作开发的靶向B7-H3的抗体偶联药物DB-1311/BNT324用于治疗未接受过紫杉烷类化疗的转移性去势抵抗性前列腺癌患者的全球Ⅲ期关键性注册临床研究已顺利完成全球首例患者入组给药。2026年5月12日，映恩生物行使独家选择权，参与分摊DB-1311/BNT324在美国地区的研发成本，并共享该药物商业化运营产生的盈亏收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2543165471.USD","BK4080","VXUS","BK1161","09606","HK0000252152.HKD","HK0000252160.HKD","BK4231","BK4588","BK4585","HK0000500386.USD","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636356678","title":"重磅ADC药物获批多发性骨髓瘤二线联合用药，GSK中国特药业务部负责人：肿瘤是未来GSK重要增长引擎之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636356678","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636356678?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:41","pubTimestamp":1779176518,"startTime":"0","endTime":"0","summary":"值得注意的是，倍乐锐是GSK肿瘤领域的重磅药物。据GSK全球一季度财报，该药物在今年一季度收入达2300万英镑，在该款药物的加持下，肿瘤业务也已经是GSK当前业绩增长最快的板块。今年第一季度，GSK肿瘤业务销售额同比增长28%，达到5.12亿英镑，业务增速在所有业务中位居第一。GSK副总裁、中国特药业务部负责人张宁向蓝鲸新闻表示，GSK未来会考虑布局更多的ADC药物、小分子药物等形成合力，包括肿瘤在内的特药业务是未来GSK很重要的增长引擎之一。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779176429659930072","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4080","BK4532","BK4231","GSK","GSK.UK","BK4007","ADC","GSKH","BK4585","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":0.0215},{"period":"1month","weight":0.0639},{"period":"3month","weight":-0.0006},{"period":"6month","weight":0.1051},{"period":"1year","weight":0.0916},{"period":"ytd","weight":0.0818}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.012831},{"month":4,"riseRate":0.59375,"avgChangeRate":0.003425},{"month":5,"riseRate":0.484848,"avgChangeRate":0.013996},{"month":6,"riseRate":0.666667,"avgChangeRate":0.010466},{"month":7,"riseRate":0.666667,"avgChangeRate":0.023025},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002201},{"month":9,"riseRate":0.46875,"avgChangeRate":-0.006321},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}